PCRX insider trading
NasdaqGS HealthcarePacira BioSciences, Inc.: insider trade history from SEC Form 4 filings.
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
Company website: www.pacira.com
PCRX insider activity at a glance
FilingIQ tracks 758 insider transactions for PCRX in filings since Jan 14, 2015. The most recent transaction is dated Aug 17, 2026.
Across the full history, 21 open-market purchases
and 346 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on PCRX insider trades is 56.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest PCRX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for PCRX?
- FilingIQ tracks 758 Form 4 insider transactions for PCRX (Pacira BioSciences, Inc.), covering filings from Jan 14, 2015 onwards. 1 of those are dated within the last 90 days.
- Are PCRX insiders net buyers or net sellers?
- Across the full Form 4 history for PCRX, 21 transactions (3%) were open-market purchases and 346 (46%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does PCRX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is PCRX in?
- Pacira BioSciences, Inc. (PCRX) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $1.09B.
Methodology & sources
Every PCRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.